tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

ACXP Stock Latest News

Acurx to sell 2.46M shares at $1.015 in registered direct offering
The FlyAcurx to sell 2.46M shares at $1.015 in registered direct offering
12d ago
ACXP
Acurx receives positive EMA guidance for ibezapolstat Phase 3 program
PremiumThe Fly
Acurx receives positive EMA guidance for ibezapolstat Phase 3 program
12d ago
ACXP
Acurx updates Phase 3 readiness for ibezapolstat in C. difficile Infection
PremiumThe Fly
Acurx updates Phase 3 readiness for ibezapolstat in C. difficile Infection
1M ago
ACXP
Acurx board approves Bitcoin as treasury reserve asset
PremiumThe Fly
Acurx board approves Bitcoin as treasury reserve asset
2M ago
ACXP
Acurx supported, participated in Peggy Lillis CDI symposium
PremiumThe Fly
Acurx supported, participated in Peggy Lillis CDI symposium
2M ago
ACXP
Acurx Pharmaceuticals Reports Promising Q3 2024 Results
PremiumCompany AnnouncementsAcurx Pharmaceuticals Reports Promising Q3 2024 Results
2M ago
ACXP
Acurx reports Q3 EPS (17c) vs. (24c) last year
Premium
The Fly
Acurx reports Q3 EPS (17c) vs. (24c) last year
2M ago
ACXP
Acurx’s ibezapostat shows favorable effect in Phase 2b CDI trial
Premium
The Fly
Acurx’s ibezapostat shows favorable effect in Phase 2b CDI trial
3M ago
ACXP
Acurx’s ibezapolstat shows positive results in CDI and Anthrax
PremiumThe Fly
Acurx’s ibezapolstat shows positive results in CDI and Anthrax
4M ago
ACXP
Acurx announces results of Phase 2 ibezapolstat trial in C. difficile Infection
PremiumThe Fly
Acurx announces results of Phase 2 ibezapolstat trial in C. difficile Infection
4M ago
ACXP
Acurx reports Q2 EPS (26c) vs (28c) last year
PremiumThe Fly
Acurx reports Q2 EPS (26c) vs (28c) last year
5M ago
ACXP
Acurx granted new patent for ibezapolstat to treat CDI
PremiumThe Fly
Acurx granted new patent for ibezapolstat to treat CDI
6M ago
ACXP
Acurx presents Phase 2 results of ibezapolstat in C. difficile Infection
PremiumThe FlyAcurx presents Phase 2 results of ibezapolstat in C. difficile Infection
6M ago
ACXP
Acurx reports results from meeting with FDA regarding ibezapolstat
Premium
The Fly
Acurx reports results from meeting with FDA regarding ibezapolstat
8M ago
ACXP
Acurx presents ibezapolstat Phase 2 clinical trial results in CDI
Premium
The Fly
Acurx presents ibezapolstat Phase 2 clinical trial results in CDI
9M ago
ACXP
Acurx price target lowered to $12 from $14 at H.C. Wainwright
PremiumThe Fly
Acurx price target lowered to $12 from $14 at H.C. Wainwright
10M ago
ACXP
Acurx files common stock offering, no amount given
PremiumThe Fly
Acurx files common stock offering, no amount given
10M ago
ACXP
Acurx’s ibezapolstat granted end of Phase 2 meeting by FDA, EMA SME designation
PremiumThe Fly
Acurx’s ibezapolstat granted end of Phase 2 meeting by FDA, EMA SME designation
11M ago
ACXP
Acurx’s antibiotic candidate shows positive Phase 2b clinical cure data
PremiumThe Fly
Acurx’s antibiotic candidate shows positive Phase 2b clinical cure data
12M ago
ACXP
Acurx announces results from ibezapolstat Phase 2b clinical trial
PremiumThe FlyAcurx announces results from ibezapolstat Phase 2b clinical trial
1y ago
ACXP
Acurx price target raised to $14 from $13 at H.C. Wainwright
Premium
The Fly
Acurx price target raised to $14 from $13 at H.C. Wainwright
1y ago
ACXP
Acurx price target raised by $1 at H.C. Wainwright, here’s why
Premium
The Fly
Acurx price target raised by $1 at H.C. Wainwright, here’s why
1y ago
ACXP

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >